Spero Therapeutics, Inc. Comprehensive Income
Spero Therapeutics, Inc. (SPRO) reported Comprehensive Income of $22.81 million for the 12-month period ending 2023-12-31, per its 10-K filed 2024-03-13.
Discontinued › Income Statement › Unrealized Gains
us-gaap:ComprehensiveIncomeNetOfTax · last filed 2024-03-13
- Spero Therapeutics, Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2023-12-31 was $51.19M, a 91.22% increase year-over-year.
- Spero Therapeutics, Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2023-09-30 was -$3.21M.
- Spero Therapeutics, Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2023-06-30 was -$11.91M.
- Spero Therapeutics, Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2023-03-31 was -$13.27M.
- Spero Therapeutics, Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2023 was $22.81M.
- Spero Therapeutics, Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2022 was -$46.41M.
- Spero Therapeutics, Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2021 was -$89.75M.
- Spero Therapeutics, Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2020 was -$78.30M.
| Period end | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 3 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 3 month as first filed | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 6 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 9 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 12 month |
|---|---|---|---|---|---|
| 2023-12-31 | $51.19M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-13 | $47.99M derived: sum of 2 quarters · filed 2024-03-13 | $36.07M derived: sum of 3 quarters · filed 2024-03-13 | $22.81M 10-K · filed 2024-03-13 | |
| 2023-09-30 | -$3.21M 10-Q · filed 2023-11-13 | -$15.12M derived: sum of 2 quarters · filed 2023-11-13 | -$28.39M 10-Q · filed 2023-11-13 | -$1.61M derived: sum of 4 quarters · filed 2024-03-13 | |
| 2023-06-30 | -$11.91M 10-Q · filed 2023-08-10 | -$25.18M 10-Q · filed 2023-08-10 | $1.59M derived: sum of 3 quarters · filed 2024-03-13 | -$10.08M derived: sum of 4 quarters · filed 2024-03-13 | |
| 2023-03-31 | -$13.27M 10-Q · filed 2023-05-11 | $13.51M derived: sum of 2 quarters · filed 2024-03-13 | $1.83M derived: sum of 3 quarters · filed 2024-03-13 | -$26.85M derived: sum of 4 quarters · filed 2024-03-13 | |
| 2022-12-31 | $26.77M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-13 | $15.10M derived: sum of 2 quarters · filed 2024-03-13 | -$13.58M derived: sum of 3 quarters · filed 2024-03-13 | -$46.41M 10-K · filed 2024-03-13 | |
| 2022-09-30 | -$11.68M 10-Q · filed 2023-11-13 | -$40.35M derived: sum of 2 quarters · filed 2023-11-13 | -$73.18M 10-Q · filed 2023-11-13 | -$102.42M derived: sum of 4 quarters · filed 2023-11-13 | |
| 2022-06-30 | -$28.68M 10-Q · filed 2023-08-10 | -$61.51M 10-Q · filed 2023-08-10 | -$90.75M derived: sum of 3 quarters · filed 2023-08-10 | -$68.23M derived: sum of 4 quarters · filed 2023-08-10 | |
| 2022-03-31 | -$32.83M 10-Q · filed 2023-05-11 | -$62.07M derived: sum of 2 quarters · filed 2023-05-11 | -$39.55M derived: sum of 3 quarters · filed 2023-05-11 | -$58.12M derived: sum of 4 quarters · filed 2023-05-11 | |
| 2021-12-31 | -$29.24M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | -$6.72M derived: sum of 2 quarters · filed 2023-03-30 | -$25.29M derived: sum of 3 quarters · filed 2023-03-30 | -$89.75M 10-K · filed 2023-03-30 | |
| 2021-09-30 | $22.52M 10-Q · filed 2022-11-14 | -$22.52M 10-Q · filed 2021-11-10 | $3.95M derived: sum of 2 quarters · filed 2022-11-14 | -$60.51M 10-Q · filed 2022-11-14 | -$34.06M derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | -$18.57M 10-Q · filed 2022-08-10 | -$37.99M 10-Q · filed 2022-08-10 | -$56.58M derived: sum of 3 quarters · filed 2022-08-10 | -$75.53M derived: sum of 4 quarters · filed 2022-08-10 | |
| 2021-03-31 | -$19.42M 10-Q · filed 2022-05-16 | -$38.01M derived: sum of 2 quarters · filed 2022-05-16 | -$56.96M derived: sum of 3 quarters · filed 2022-05-16 | -$74.43M derived: sum of 4 quarters · filed 2022-05-16 | |
| 2020-12-31 | -$18.59M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | -$37.54M derived: sum of 2 quarters · filed 2022-03-31 | -$55.01M derived: sum of 3 quarters · filed 2022-03-31 | -$78.30M 10-K · filed 2022-03-31 | |
| 2020-09-30 | -$18.95M 10-Q · filed 2021-11-10 | -$36.42M derived: sum of 2 quarters · filed 2021-11-10 | -$59.71M 10-Q · filed 2021-11-10 | -$84.70M derived: sum of 4 quarters · filed 2021-11-10 | |
| 2020-06-30 | -$17.47M 10-Q · filed 2021-08-05 | -$40.76M 10-Q · filed 2021-08-05 | -$65.75M derived: sum of 3 quarters · filed 2021-08-05 | -$83.45M derived: sum of 4 quarters · filed 2021-08-05 | |
| 2020-03-31 | -$23.29M 10-Q · filed 2021-05-06 | -$48.28M derived: sum of 2 quarters · filed 2021-05-06 | -$65.99M derived: sum of 3 quarters · filed 2021-05-06 | -$79.13M derived: sum of 4 quarters · filed 2021-05-06 | |
| 2019-12-31 | -$24.99M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-11 | -$42.69M derived: sum of 2 quarters · filed 2021-03-11 | -$55.84M derived: sum of 3 quarters · filed 2021-03-11 | -$60.88M 10-K · filed 2021-03-11 | |
| 2019-09-30 | -$17.70M 10-Q · filed 2020-11-05 | -$30.85M derived: sum of 2 quarters · filed 2020-11-05 | -$35.89M 10-Q · filed 2020-11-05 | -$46.50M derived: sum of 4 quarters · filed 2020-11-05 | |
| 2019-06-30 | -$13.14M 10-Q · filed 2020-08-06 | -$18.19M 10-Q · filed 2020-08-06 | -$28.79M derived: sum of 3 quarters · filed 2020-08-06 | -$39.26M derived: sum of 4 quarters · filed 2020-08-06 | |
| 2019-03-31 | -$5.04M 10-Q · filed 2020-05-08 | -$15.65M derived: sum of 2 quarters · filed 2020-05-08 | -$26.12M derived: sum of 3 quarters · filed 2020-05-08 | -$36.06M derived: sum of 4 quarters · filed 2020-05-08 | |
| 2018-12-31 | -$10.60M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-16 | -$21.07M derived: sum of 2 quarters · filed 2020-03-16 | -$31.02M derived: sum of 3 quarters · filed 2020-03-16 | -$41.69M 10-K · filed 2020-03-16 | |
| 2018-09-30 | -$10.47M 10-Q · filed 2019-11-04 | -$20.41M derived: sum of 2 quarters · filed 2019-11-04 | -$31.09M 10-Q · filed 2019-11-04 | -$44.95M derived: sum of 4 quarters · filed 2019-11-04 | |
| 2018-06-30 | -$9.94M 10-Q · filed 2019-08-08 | -$20.61M 10-Q · filed 2019-08-08 | -$34.48M derived: sum of 3 quarters · filed 2019-08-08 | -$44.33M derived: sum of 4 quarters · filed 2019-08-08 | |
| 2018-03-31 | -$10.67M 10-Q · filed 2019-05-09 | -$24.54M derived: sum of 2 quarters · filed 2019-05-09 | -$34.38M derived: sum of 3 quarters · filed 2019-05-09 | -$44.15M derived: sum of 4 quarters · filed 2019-05-09 | |
| 2017-12-31 | -$13.87M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-14 | -$23.71M derived: sum of 2 quarters · filed 2019-03-14 | -$33.48M derived: sum of 3 quarters · filed 2019-03-14 | -$39.89M 10-K · filed 2019-03-14 | |
| 2017-09-30 | -$9.84M 10-Q · filed 2018-11-08 | -$19.61M derived: sum of 2 quarters · filed 2018-11-08 | -$26.02M 10-Q · filed 2018-11-08 | ||
| 2017-06-30 | -$9.76M 10-Q · filed 2018-08-09 | -$16.17M 10-Q · filed 2018-08-09 | |||
| 2017-03-31 | -$6.41M 10-Q · filed 2018-05-10 | ||||
| 2016-12-31 | -$32.64M 10-K · filed 2019-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| PMV Pharmaceuticals, Inc. (PMVP) | United States | $0.071B | -0.95 |
| TENAX THERAPEUTICS, INC. (TENX) | United States | $0.071B | -7.17 |
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| Connect Biopharma Holdings Ltd (CNTB) | $0.069B | -2.17 |